Posaconazole Plasma Concentrations in Juvenile Patients With Invasive Fungal Infection

Gopal Krishna*, Angela Sansone-Parsons, Monika Martinho, Bhavna Kantesaria, and Lisa Pedicone

Schering-Plough Research Institute, Kenilworth, New Jersey

Running title: Posaconazole Pharmacokinetics in Juvenile Patients

Key words:azole, children, pharmacokinetics, posaconazole safety

*Corresponding Author. Mailing address: Schering-Plough Research Institute, K-15-2, 2650 Galloping Hill Road, Kenilworth, New Jersey, 07033, USA. Tel.: +1 908 740 6564; Fax: +1 908 740 2916; email: gopal.krishna@spcorp.com
ABSTRACT

Posaconazole is an orally bioavailable triazole antifungal agent for the treatment and prophylaxis of invasive fungal infection. We evaluated plasma posaconazole concentration data from juvenile (younger than 18 years, \( n = 12 \)) and adult (18 to 64 years, \( n = 194 \)) patients who participated in a multicenter, phase 3, open-label study that assessed the efficacy and safety of posaconazole treatment in persons who were intolerant of or had invasive fungal infection refractory to standard antifungal therapies. With the exception of 1 juvenile patient who received 400 mg/day as a divided dose on the day of sample collection, all patients received posaconazole 800 mg/day as an oral suspension in divided doses. Plasma samples were analyzed through a validated liquid chromatographic-tandem mass spectrometric method with a lower limit of quantitation of 1 ng/mL. Because plasma posaconazole concentrations are relatively constant at steady state, the average of all plasma concentrations (\( C_{av} \)) for each patient was calculated to provide a single steady state plasma posaconazole concentration. A blinded data review committee reviewed all treatment outcomes. Variable posaconazole plasma concentrations were observed within both the juvenile and adult populations. Mean (median [range]) \( C_{av} \) values in juvenile and adult patients were 776 ng/mL (579 ng/mL [85.3-2,891 ng/mL]) and 817 ng/mL (626 ng/mL [0-3,710 ng/mL]), respectively. Overall success rates and adverse event profiles were comparable. In conclusion, posaconazole plasma concentration values were similar in juvenile and adult patients, suggesting that clinical outcomes are expected to be similar in adults and children with refractory invasive fungal infection.
INTRODUCTION

Posaconazole is an extended-spectrum triazole antifungal used for the treatment and prophylaxis of refractory invasive fungal infection (13). In vitro studies have shown that posaconazole is active against many common yeasts and moulds, including *Candida* and *Aspergillus*, as well as against *Fusarium*, *Coccidioides*, Zygomycetes, and other filamentous and dimorphic fungi (2, 8, 9, 11, 13, 18-21, 27). In addition, posaconazole has been shown to be clinically effective in adult patients who have invasive fungal infections, including aspergillosis, zygomycosis, and candidiasis, and who are intolerant of or have disease refractory to other antifungal agents (28).

The pharmacokinetics of posaconazole have been well characterized in healthy adults. After rising single or multiple oral doses, plasma concentrations increase in a dose-proportional manner up to 800 mg/day (5), and steady state concentrations are achieved after 7 to 10 days of dosing (400 mg twice daily or 200 mg four times daily) (5, 10). The median time to peak posaconazole plasma concentration ($T_{\text{max}}$) is approximately 3 to 5 hours (data on file; Schering-Plough Research Institute, Kenilworth, NJ). Optimal exposure is achieved when 800 mg posaconazole is administered as an oral suspension in divided doses with food (6, 10).

Posaconazole is eliminated primarily as parent compound in feces, and the primary metabolic pathway is glucuronidation (14). Oxidative metabolism by cytochrome P450 (CYP) isoforms represents only a minor route of elimination. Posaconazole inhibits hepatic CYP3A4 activity but has no significant effect on CYP1A2, CYP2C8/9, CYP2D6, or CYP2E1 (30). Posaconazole is slowly eliminated, with a terminal phase half-life ($t_{1/2}$) of approximately 35 hours at steady state (data on file; Schering-Plough Research Institute, Kenilworth, NJ). As a result of the long terminal phase half life, the steady state plasma concentration–time profile of posaconazole after
twice-daily dosing of 400 mg is relatively flat, with minimal differences in observed maximum
plasma concentration ($C_{\text{max}}$) and observed minimum plasma concentration ($C_{\text{min}}$) values (5).

Salvage therapy for invasive fungal infections in children remains a therapeutic challenge that is
often complicated by a delay in the conduct of definitive pediatric studies for new agents.
Although investigation of the pharmacokinetic profile of a drug in children is often delayed
during the drug development process, results have been published of studies examining the
pharmacokinetics in pediatric patients of currently marketed azole antifungals, such as
itraconazole (7, 12, 25), fluconazole (3, 15, 16, 26), and voriconazole (29). Pharmacokinetic
profiles for itraconazole are inconsistent between pediatric patients and adults, and some
pharmacokinetic parameters of fluconazole and voriconazole appear to differ between children
and adults.

The primary objective of this analysis was to report available, albeit limited, plasma
posaconazole concentration data from patients younger than 18 years of age and compare these
data with those of adult patients. Secondary objectives were to analyze efficacy in the juvenile
population and compare safety profiles of posaconazole in juvenile and adult patients.

MATERIALS AND METHODS

Patient population

Patients were participants in a multicenter, phase 3, open-label study that assessed the efficacy
and safety of posaconazole treatment in patients who were intolerant of or who had invasive
fungal infection refractory to standard antifungal therapies. The intent-to-treat (ITT) subset
included all patients who received at least 1 dose of posaconazole, and the modified intent-to-
treat (MITT) subset included only those patients from the ITT subset who had a proven or
probable invasive fungal infection (based on European Organisation for Research and Treatment
of Cancer/Mycoses Study Group [EORTC/MSG] criteria) (1). Three hundred thirty patients were
included in the ITT population; 238 were included in the MITT population. Within the ITT
subset, sufficient pharmacokinetic data were available for a subset of 206 patients—12 juvenile
patients (younger than 18 years) and 194 adult patients (18 to 64 years).

This study was conducted in accordance with the Declaration of Helsinki and was approved by
an accredited institutional review board. All patients provided written informed consent. For
patients younger than 18 years, a parent or a legal guardian gave written informed consent before
study entry.

Inclusion and exclusion criteria
Patients with proven or probable invasive fungal infection according to the EORTC/MSG criteria
(1) and evidence of intolerance of or disease refractory to other antifungal therapies were eligible
for study participation. Patients were considered intolerant of available antifungal therapies if
they had any of the following: (1) history of serious, severe, or life-threatening toxicity (i.e.,
organ toxicity ≥ grade 3) while receiving antifungal therapy, nephrotoxicity (i.e., persistent
serum creatinine >2 times the upper limit of normal [ULN] or recurrent serum creatinine >2
times the ULN after resumption of amphotericin B therapy); (2) preexisting organ dysfunction,
including renal insufficiency, that precluded the use of standard antifungal therapies; (3) high
risk for toxicity because of underlying disease or concomitant medications; or (4) previous major
idiosyncratic or hypersensitivity reaction to antifungal agents. Patients were considered to have
disease refractory to standard therapies (e.g., amphotericin B, other azoles) if they experienced
disease progression or if they showed no clinical improvement during antifungal therapy given
for an adequate period of time (e.g., 10 to 14 days for cryptococcal meningitis, 7 days for
infections caused by *Aspergillus* spp, 14 days for infections caused by non-*Aspergillus* moulds,
30 days for histoplasmosis, and 180 days of azole therapy for coccidioidomycosis).

Patients were ineligible for study participation if they had concurrent progressive neurologic
disease (e.g., seizures, demyelinating syndromes, unstable multiple sclerosis, peripheral
neuropathy), required artificial ventilation and were unlikely to undergo extubation within 24
hours of study entry, had a history of serious or severe hypersensitivity to azole antifungals,
received medications that are known to interact with azoles and may lead to life-threatening
adverse events (i.e., terfenadine, cisapride, ebastine at entry or within 24 hours before therapy, or
astemizole at entry or within 10 days of study entry), received drugs that lower azole serum
concentrations (e.g., rifampin, phenytoin) within 7 days of study entry, had electrocardiography
results showing prolonged QTc interval (≥20% above normal) within 7 days of study entry,
needed concomitant systemic antifungal agents during the study period, had significantly
abnormal hepatic function test results (alanine aminotransferase or aspartate aminotransferase
>10 times the ULN), or were expected to survive less than 72 hours. Women were excluded from
participation if they were pregnant or lactating, were using inadequate contraception, or had not
undergone surgical sterilization.
Treatment

Patients received posaconazole as an oral suspension at doses of 200 mg four times daily or 400 mg twice daily while hospitalized, and then at a dose of 400 mg twice daily after discharge from the hospital.

Pharmacokinetic analysis

Blood samples (6 mL) for determining posaconazole concentrations in juvenile patients 13 years of age or older were to be collected before and after the first daily dose, at approximately 0, 2, 4, and 6 hours at week 2 and approximately 30 minutes before the first daily dose and along with the adult patients at 2 to 4 hours after that dose at week 16. However, the blood collection schedule for the juvenile population could not be strictly followed. On a given day, 2 to 6 samples were taken from 11 patients, and from 1 patient a single sample was collected.

Plasma was separated via centrifugation and stored frozen at –20°C until it could be analyzed. To determine posaconazole concentrations, plasma samples were analyzed using a positive-ion Turbo IonSpray (PE Applied Biosystems, Foster City, CA) liquid chromatographic-tandem mass spectrometric (LC-MS-MS) method. The calibration range was 1.00 to 4,000 ng/mL.

Between-run accuracy (percentage difference from actual value) values of the quality control (QC) for lower limit of quantitation (LLOQ; 1.00 ng/mL), low (3.00 ng/mL), medium (1,500 ng/mL), and high (3,000 ng/mL) QC samples were –7.59, –1.31, –0.504, and –3.71, respectively. Between-run precision (percentage coefficient of variation) values of the QC samples at LLOQ, low, medium, and high concentrations were 15.7, 9.49, 7.07, and 8.54, respectively.
Because posaconazole is slowly eliminated and has a long terminal phase half life ($t_{1/2}$) of 35 hours, a twice-daily or four times daily dosing regimen provides plasma concentrations that are relatively flat and unchanged over time at steady state. Thus, the average of all the plasma concentrations ($C_{av}$) in a patient was calculated to provide a single steady state plasma posaconazole concentration for each patient. Descriptive statistics (mean, median, standard deviation, minimum, and maximum) using each patient’s $C_{av}$ values were then calculated by age group. Juvenile pharmacokinetic data (composite plasma concentration–time plots and $C_{av}$) were compared with data from adult patients.

**Data review committee**

A blinded data-review committee (DRC) composed of 17 experts in the diagnosis and treatment ($n = 15$) or in the radiographic analysis of invasive fungal infections ($n = 2$) reviewed each case to ensure that all patients met predetermined eligibility criteria. Teams of 2 or 3 DRC members determined eligibility and outcomes using predefined criteria. The DRC reviewed treatment outcomes at month 1, month 3, month 6 and at the end of therapy (or at 12 months if treatment went beyond that time).

**Efficacy definitions**

Successful outcome was defined as the resolution of all attributable symptoms, signs, and radiographic abnormalities (complete response) or as clinically meaningful improvement in attributable symptoms, signs, and radiographic abnormalities (partial response). Nonsuccessful outcome was defined as no improvement in attributable symptoms, signs, and radiographic abnormalities.
abnormalities (stable disease) or deterioration in attributable clinical or radiographic abnormalities that necessitated alternative antifungal therapy or resulted in death (treatment failure). If for any reason the response could not be assessed, the patient was considered to have had a nonsuccessful outcome.

Safety analysis

Reported adverse events (spontaneously reported, solicited via generalized questioning, or identified during routine laboratory testing or physical examination), clinical laboratory test results, measurements of vital signs, and electrocardiograms were used to assess safety (24). Investigators determined whether each adverse event was unlikely, possibly, or probably related to posaconazole treatment. A treatment-related adverse event was defined as any event the investigator considered to be at least possibly related to posaconazole treatment or for which the investigator did not assign a relationship (i.e., any adverse event not specifically considered to be unlikely related to treatment).

RESULTS

Patient demographics

Of the 12 juvenile patients evaluated, 7 were boys and 5 were girls. Baseline age and body weight ranged from 8 to 17 years and from 24 to 76 kg, respectively (Table 1). Most juvenile patients had hematologic malignancies; 4 also underwent bone marrow transplantation.

Pharmacokinetic data were available for 194 adult patients (age, 18 to 64 years) and were used for comparison with data for the juvenile population. Of the adult patients, 129 were men and 65
were women. The average age of the adult patient group was approximately 41 years. Most patients (102 of 194) were white; body weight in this group ranged from 29.5 to 119.6 kg.

Pharmacokinetics

Eleven juvenile patients received a maintenance dose of 800 mg/day posaconazole oral suspension in divided doses. One patient (patient #1) received 400 mg/day posaconazole in divided doses on the day of sample collection and 800 mg/day in divided doses before the day of sample collection. Adult patients received posaconazole 800 mg/day in divided doses.

All infections

Posaconazole $C_{av}$ values in juvenile and adult patients were comparable. Mean posaconazole $C_{av}$ values were 776 ng/mL in juvenile patients and 817 ng/mL in adult patients (Table 2). Maximum posaconazole $C_{av}$ values were 2,891 ng/mL and 3,710 ng/mL, respectively. Minimum posaconazole $C_{av}$ values in juveniles and adults were 85.3 ng/mL and 0 ng/mL, respectively. Individual $C_{av}$ values for juvenile patients are shown in Table 3. Composite plasma concentration–time profiles were relatively flat for both the juvenile and adult populations (Figs. 1 and 2). The range of plasma posaconazole concentration values showed considerable overlap between the adult and juvenile groups, indicating that the $C_{av}$ values in these 2 age groups were similar (Fig. 3). However, because of the disparity between the juvenile and adult sample sizes, definitive conclusions cannot be made. Interpatient variability of posaconazole plasma concentration has been noted in both patient populations. As shown in Fig. 4A-C, no association was apparent between age, body weight, or body surface area and posaconazole $C_{av}$ ($R^2 = 0.06$, $R^2 = 0.05$, and $R^2 = 0.02$, respectively).
Aspergillus infections

Plasma posaconazole concentrations were also analyzed for the subset of patients who had *Aspergillus* infections (patients #s 1, 3, 5, 10, and 11) because these were the most common fungal infections observed in the present study and are the most frequently treated fungal infection in clinical practice. Although the pharmacokinetic data in the juvenile population were drawn from a small sample size (*n* = 5), the pharmacokinetic parameters were comparable to those of adults. Mean plasma posaconazole $C_{av}$ values were 1,058 ng/mL in juvenile patients and 684 ng/mL in adult patients (Table 2). Maximum plasma posaconazole $C_{av}$ values were 2,891 ng/mL and 3,340 ng/mL in juvenile and adult patients, respectively. Minimum posaconazole $C_{av}$ values in juveniles and adults were 85.3 ng/mL and 32.5 ng/mL, respectively.

Clinical efficacy in the juvenile population

Eight patients were included in the MITT group. Six patients had disease that was considered refractory to available antifungal therapy, 1 was considered intolerant of available antifungal therapy, and 1 was considered both refractory and intolerant.

Successful outcomes were observed in 5 of 8 (62.5%) MITT patients who had infections caused by *Aspergillus* (patient #s 1, 3), *Candida* (patient # 7), *Coccidioides* (patient # 12), and *Scedosporium* (patient # 11) (Table 3). Nonsuccessful outcomes were observed in 3 (37.5%) patients who had infections caused by *Candida, Aspergillus, or Fusarium.*
Four patients were not included by the DRC in the MITT subset but were included in the pharmacokinetic analysis. One of these patients had a possible infection (Candida albicans [patient # 9]), and 3 patients were not considered to have refractory disease or to be intolerant of standard therapy, though they had proven fungal infections (Fusarium species [patient # 6], C. albicans [patient # 8], Aspergillus species [patient # 5]). All 4 of these patients had successful outcomes with posaconazole.

Safety

Of the 12 juvenile patients, 8 completed the study. Four patients discontinued prematurely because of adverse events. These adverse events were considered unlikely related to posaconazole treatment in 3 patients and possibly related (convulsions, cardiorespiratory arrest) in 1 of them.

Three deaths occurred in the juvenile population during the study. Two (patient #s 2, 7) were considered unlikely to be related to posaconazole therapy (1 resulted from invasive fungal infection and the other from progression of acute lymphoblastic leukemia). The primary cause of death in the third patient (patient # 10) was attributed to adverse events considered by the investigator to be possibly related to posaconazole treatment. The patient, a 16-year-old girl with a history of acute lymphoblastic leukemia, allogeneic bone marrow transplantation, and seizures, died on day 95 (1 day after the last dose of posaconazole) from cardiorespiratory failure after a prolonged seizure at home. Although the investigator could not eliminate posaconazole as a possible cause of the seizure, the event was most likely a recurrence of seizures noted before
baseline. A fourth patient (patient # 6), who had a complete response to posaconazole, died of progressive osteosarcoma 34 days after receiving the last posaconazole dose.

Posaconazole was generally safe and well tolerated in these juvenile patients, with only 2 patients reporting vomiting (1 with concomitant nausea) possibly related to posaconazole (Table 3). In addition, 2 patients experienced renal insufficiency (possibly related to study treatment). In this small series of patients, there was no clear relationship between the duration of posaconazole exposure and the emergence of treatment-related adverse events.

Overall, the treatment-related adverse events were similar among juvenile and adult patients and consistent with a profoundly immunocompromised patient population with severe underlying disease. In the juvenile population, 3 of 7 (43%) treatment-related adverse events were gastrointestinal. The most common (≥5%) treatment-related adverse events in the overall population (adult and juvenile) were nausea (9%), vomiting (6%), abdominal pain (5%), and headache (5%) (24).

Elevated liver function test results were reported in 2 juvenile patients: 1 patient (patient # 4) had mild alanine aminotransferase elevation, and 1 patient (patient # 7) had a moderate aspartate aminotransferase elevation. Both of these elevations were deemed unlikely to be related to posaconazole treatment.
DISCUSSION

This analysis compared posaconazole plasma $C_{av}$ values in 12 juvenile patients with those in 194 adult patients. Patients enrolled in this phase 3 open-label clinical trial had invasive fungal infection and were intolerant of or had disease refractory to standard therapies. Our pharmacokinetic analysis showed that the range of posaconazole plasma $C_{av}$ values were similar in juvenile and adult patients, with mean values of 776 ng/mL and 817 ng/mL, respectively. A secondary finding was that posaconazole was efficacious in 5 of 8 (62.5%) juvenile patients, was generally safe and well tolerated, and had similar adverse event profiles in both juvenile and adult patients.

Results of studies examining the pediatric/juvenile pharmacokinetics of currently marketed azole antifungals, such as itraconazole (7, 12, 25), fluconazole (3, 15, 16, 26), and voriconazole (29) have been published. Two studies (12, 25) with itraconazole show similar peak and trough concentrations in pediatric and adult patients (17 patients, ages 2 to 18 years), and another (7) reports pediatric concentrations that were approximately one third of those attained by adults (26 patients, ages 6 months to 12 years) (4, 7, 22, 23). The difference between pediatric and adult patients may result in part from greater itraconazole clearance in younger children (25). Fluconazole has an age-dependent volume of distribution that is greatest in neonates and decreases by young adulthood to values approaching those in adults (562 patients, ages 0 to 17) (3, 17). Compared with adults, fluconazole is eliminated much more slowly in neonates and premature infants and more rapidly in other pediatric patients (3, 17). Voriconazole is eliminated more rapidly in pediatric patients than it is in adult patients (35 patients, ages 2 to 11) (29).
In these studies, the safety profiles of itraconazole, fluconazole, and voriconazole were similar in adult and pediatric patients. In both adults and children, the adverse events most frequently reported with itraconazole (7, 12) and fluconazole (17) were gastrointestinal. Transient visual disturbances were the most common adverse events associated with voriconazole in children and in adults (29).

Our investigation focused on plasma posaconazole concentrations at an early stage of the drug development program and did not seek to provide exhaustive comparative data on the pharmacokinetics of posaconazole in juvenile and adult patients. In addition, the ITT population on which our analysis is based was limited to 12 juvenile patients, compared with 194 adults. Furthermore, the blood collection schedule for the juvenile population could not be strictly followed during the trial. However, limited plasma concentration data in juvenile patients did reveal a relatively flat steady state profile consistent with a long terminal phase half-life, as in adults. Although data are limited, a lack of association was apparent between posaconazole plasma $C_{av}$ and age, body weight, or body surface area. Posaconazole $C_{av}$ values in the youngest (8-year-old) patient (227 ng/mL) and oldest (17-year-old) subject (238 ng/mL) were similar. It is noteworthy that some protocol deviations also occurred in juvenile studies with fluconazole; these deviations resulted from the clinical condition of the patients and from the priority given to their well-being rather than to the pharmacokinetic objectives of the studies (3).

Despite the limitations of the study and observed variability in concentrations within the juvenile and adult patient populations, the range of plasma posaconazole concentration values were similar in juvenile and adult patients with invasive fungal infection who were intolerant of or
who had disease refractory to other antifungal therapy. There did not appear to be any
association between $C_{av}$ and treatment-related adverse events. A definitive relationship between
plasma azole concentrations and clinical outcome has not been firmly established. Nevertheless,
the similarity in concentrations suggests that clinical outcomes are expected to be similar in
adults and children with refractory invasive fungal infection who receive posaconazole therapy.
Our characterization of the plasma concentration–time profile of posaconazole in children
supports the ongoing evaluation and management of this drug in juvenile patients with refractory
invasive fungal infection.
REFERENCES


TABLE 1. Demographics and baseline characteristics of juvenile patients

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age, yr</th>
<th>Weight, kg</th>
<th>Gender</th>
<th>Underlying Disease</th>
<th>Baseline Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8</td>
<td>39.4</td>
<td>M</td>
<td>Burkitt lymphoma, AML</td>
<td>Aspergillus spp</td>
</tr>
<tr>
<td>2</td>
<td>10</td>
<td>51.7</td>
<td>M</td>
<td>CML, allogeneic BMT</td>
<td>Fusarium spp</td>
</tr>
<tr>
<td>3</td>
<td>12</td>
<td>24</td>
<td>M</td>
<td>Chronic granulomatous disease</td>
<td>Aspergillus fumigatus</td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>36.7</td>
<td>M</td>
<td>AML</td>
<td>Candida spp</td>
</tr>
<tr>
<td>5</td>
<td>14</td>
<td>34.5</td>
<td>F</td>
<td>Cystic fibrosis</td>
<td>Aspergillus spp</td>
</tr>
<tr>
<td>6</td>
<td>15</td>
<td>54.5</td>
<td>F</td>
<td>Osteosarcoma</td>
<td>Fusarium spp</td>
</tr>
<tr>
<td>7</td>
<td>15</td>
<td>76</td>
<td>M</td>
<td>ALL</td>
<td>Candida krusei</td>
</tr>
<tr>
<td>8</td>
<td>15</td>
<td>53.3</td>
<td>M</td>
<td>AML, allogeneic BMT</td>
<td>Candida albicans</td>
</tr>
<tr>
<td>9</td>
<td>16</td>
<td>40.6</td>
<td>F</td>
<td>Inherited immunodeficiency</td>
<td>Candida albicans</td>
</tr>
<tr>
<td>10</td>
<td>16</td>
<td>36</td>
<td>F</td>
<td>ALL, allogeneic BMT</td>
<td>Aspergillus spp</td>
</tr>
<tr>
<td>11</td>
<td>16</td>
<td>59.9</td>
<td>M</td>
<td>CML, allogeneic BMT</td>
<td>Scedosporium apiospermum</td>
</tr>
<tr>
<td>12</td>
<td>17</td>
<td>45.4</td>
<td>F</td>
<td>None</td>
<td>Coccidioides immitis</td>
</tr>
</tbody>
</table>

ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BMT, bone marrow transplantation; CML, chronic myelogenous leukemia
TABLE 2. Posaconazole plasma concentrations (ng/mL) in adult and juvenile patients in the intent-to-treat population

<table>
<thead>
<tr>
<th>Patients</th>
<th>Median Concentration</th>
<th>Mean (SD) Concentration</th>
<th>Minimum Concentration</th>
<th>Maximum Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>All infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 juvenile</td>
<td>579</td>
<td>776 (769)</td>
<td>85.3</td>
<td>2,891</td>
</tr>
<tr>
<td>194 adult</td>
<td>626</td>
<td>817 (689)</td>
<td>0</td>
<td>3,710</td>
</tr>
<tr>
<td>Aspergillus infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 juvenile</td>
<td>927</td>
<td>1,058 (1,120)</td>
<td>85.3</td>
<td>2,891</td>
</tr>
<tr>
<td>77 adult</td>
<td>530</td>
<td>684 (642)</td>
<td>32.5</td>
<td>3,340</td>
</tr>
</tbody>
</table>

All plasma concentrations are expressed in ng/mL.
TABLE 3. Individual plasma concentrations, clinical response*, and treatment-related adverse events

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age, yr</th>
<th>Weight, kg</th>
<th>Posaconazole C&lt;sub&gt;av&lt;/sub&gt; (ng/mL)</th>
<th>Clinical Response</th>
<th>Treatment-Related Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>8</td>
<td>39.4</td>
<td>227</td>
<td>PR</td>
<td>Vomiting, Nausea</td>
</tr>
<tr>
<td>2</td>
<td>10</td>
<td>51.7</td>
<td>140</td>
<td>FL</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>12</td>
<td>24</td>
<td>85</td>
<td>PR</td>
<td>Renal insufficiency</td>
</tr>
<tr>
<td>4</td>
<td>12</td>
<td>36.7</td>
<td>1112</td>
<td>SD</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>14</td>
<td>34.5</td>
<td>2891</td>
<td>NA†</td>
<td>Renal failure</td>
</tr>
<tr>
<td>6</td>
<td>15</td>
<td>54.5</td>
<td>396</td>
<td>NA†</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>15</td>
<td>76</td>
<td>546</td>
<td>CR</td>
<td>Vomiting</td>
</tr>
<tr>
<td>8</td>
<td>15</td>
<td>53.3</td>
<td>613</td>
<td>NA†</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>16</td>
<td>40.6</td>
<td>982</td>
<td>NA†</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>16</td>
<td>36</td>
<td>1161</td>
<td>UTD</td>
<td>Cardio-respiratory arrest; Convulsions</td>
</tr>
<tr>
<td>11</td>
<td>16</td>
<td>59.9</td>
<td>927</td>
<td>CR</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>17</td>
<td>45.4</td>
<td>238</td>
<td>PR</td>
<td></td>
</tr>
</tbody>
</table>

*Received 400 mg/day posaconazole in divided doses on the day of sample collection, and 800 mg/day in divided doses before the day of sample collection
†Only MITT population included in clinical response, patients stopped treatment due to an adverse event
CR indicates complete response; FL, failure; NA, not applicable; PR, partial response; SD, stable disease; UTD, unable to determine
FIG. 1. Composite posaconazole plasma concentration–time profile showing observed plasma concentration values in the juvenile population (younger than 18 years).
FIG. 2. Composite posaconazole plasma concentration–time profile showing observed plasma concentration values in the adult population (18 to 64 years).
FIG. 3. Individual mean posaconazole $C_{av}$ values in the juvenile ($n = 12$) and adult ($n = 194$) populations. The lower and upper limits of the box represent the 25th and 75th percentiles, respectively; the horizontal line within the box represents the median value, and the upper and lower whiskers represent the 10th and 90th percentiles; data points beyond the whiskers represent possible outliers.
FIG. 4. Comparison of posaconazole $C_{a,v}$ and (A) age, (B) body weight, and (C) body surface area.

A.